Zevra Therapeutics (ZVRA) Short-term Investments (2015 - 2026)

Zevra Therapeutics has reported Short-term Investments for 9 years, with the latest figure at $105.0 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 315.25% year-over-year to $105.0 million; the trailing twelve-month figure through Mar 2026 stood at $105.0 million (up 315.25% YoY), and the FY2025 full-year result was $128.6 million, up 260.13% from the prior year.
• Short-term Investments for Q1 2026 stood at $105.0 million, down from $128.6 million in the prior quarter.
• The five-year high for Short-term Investments was $154.9 million in Q2 2025, with the low at $4.2 million in Q2 2022.
• Historically, Short-term Investments has averaged $58.0 million across 5 years, with a median of $30.3 million in 2024.
• Annual changes were most pronounced in 2024 — Short-term Investments jumped 44.65% — and 2025, when it surged 1449.3%.
• Zevra Therapeutics' Short-term Investments stood at $16.9 million in 2022, then surged by 46.08% to $24.7 million in 2023, then soared by 44.65% to $35.7 million in 2024, then surged by 260.13% to $128.6 million in 2025, then fell by 18.34% to $105.0 million in 2026.
• The last three Short-term Investments figures came in at $105.0 million (Q1 2026), $128.6 million (Q4 2025), and $145.1 million (Q3 2025), per Business Quant data.